THE
ARCHIVES

Week of September 14th, 2026. Semaglutide started in old mice extended median lifespan by roughly 12% and beat matched calorie restriction on memory and glucose. Plus the checkpoint senescent cells use to evade immune clearance, the first genome-wide evidence that diet slows mutation accrual, why an Alzheimer's blood test only reads properly alongside APOE, a clean negative heart failure trial, chemotherapy's mutational cost in a child's liver, and the stem cell behind lumbar

Week of September 7th, 2026 The thread running through this week's research is subtraction: things your body quietly stops making, stops clearing, or starts making in the wrong place. We lead with a first-in-human trial in which a single injection knocked lipoprotein(a) down by up to 97% and held it there for nearly a year, then the phase 3 outcomes trial that spent seven years asking whether lowering that number actually prevents heart attacks and came back with an answer no

Week of August 31st, 2026 The thread running through this week's research is stubbornly consistent: aging looks less like machinery wearing out and more like an immune system that never quite stands down, and the interventions that matter are the ones that quiet it. We cover a Yale team that traced the anti-aging benefit of calorie restriction to a single immune protein made in your belly fat, a natural experiment from postwar Britain showing that sugar exposure before your s

Week of August 24th, 2026 The thread running through this week's research is size: not whether something works, but how much, and how much of the headline number survives contact with an honest analysis. We cover a Swedish screening program that separates the benefit of getting the invitation from the benefit of actually mailing the kit back, autopsy data that complicates twenty years of warnings about estrogen and dementia, a genomic detective story showing that immune cells

Week of August 17th, 2026 This week the research keeps pointing back to the body's own machinery: the hormones, brain rhythms, membrane lipids, and social wiring you already have, and how much of aging turns on whether they hold up. We cover a randomized trial testing whether semaglutide can quiet heavy drinking, a wearable study suggesting three minutes of daily huffing-and-puffing lowers cancer risk as much as an hour and a half of strolling, and a thymus hormone called thy

Week of August 10th, 2026 The thread running through this week’s research is granularity: the field keeps zooming in, from whole organs down to single cells and single molecules, and finding that the action is at the fine scale. We cover a Stanford peptide just twelve amino acids long that curbs appetite like semaglutide but skips the nausea, a Wistar discovery that a common dietary sugar acts as a chemical "get loose and spread" signal to cancer cells, and a bioengineered ch

Week of August 3, 2026 There's a quiet theme running through this week's research: the things we assume are helping us often do less than the label promises, and the ordinary inputs we treat as trivial — an hour of sleep, a museum ticket, the plastic in our water, the coffee already in our hands — may matter more than the supplements we spend money on. A landmark heart study finds micro- and nanoplastics far more often in the blood of people mid-heart-attack than in healthy a

Week of August 3, 2026 This week's research focuses one idea: the assumed culprit is often not the real one, and catching a problem before it declares itself beats treating it after. A first-in-human vaccine intercepts pancreatic cancer in high-risk patients before a tumor ever forms, while a University of Kentucky team found that Alzheimer's sleep loss comes not from amyloid plaques but from the brain's own immune cells overreacting to them. A $100 million trial is testing w

This week: precision-matched GLP-1 therapy, a biological heart-age biomarker, a new Parkinson's inflammaging mechanism, a stool-based colorectal cancer signature, what diet actually does to senescent cells, a mitochondria-peroxisome longevity link, and a gut-microbiome frailty predictor in older women. Evidence-graded, seven findings, no filler.

Week of July 20th, 2026 This week's research keeps circling one divide: the distance between a beautiful mechanism and something you can actually do on Monday morning. We cover a major trial that finally gives the other half of kidney patients a drug that works, fresh epigenetic-clock data suggesting semaglutide nudges biological aging, and a "longevity diet" whose trick turns out to be raising your own growth hormone and GLP-1 rather than cutting protein wholesale. Plus: why

Week of July 10th, 2026 This week’s research keeps circling one theme: the difference between what sounds actionable and what actually is. We dig into the blood chemistry that sets centenarians apart (and why you can’t supplement your way to it), a molecular “switch” that explains how exercise reverses muscle aging, with a catch about timing that should change how you think about training in midlife, and a head-to-head trial on whether intermittent fasting really beats calori

Seven things worth reading this week: four on longevity and health, three on performance and fitness. We spent last week on the GLP-1 wave, so this week we sit that one out. What's left is arguably more useful anyway — the levers you can actually pull. Longevity & Health 1. What your "biological age" actually means Biological-age tests are everywhere now, a swab, a fee, and a number that says you're "really" 47 or 61. This overview steps back and asks the harder question: are

Seven research findings for your longevity strategy -- protein guidelines challenged, GLP-1s become official first-line obesity treatment, fish oil fails a two-year Alzheimer's trial, palmitic vs. oleic acid and diabetes risk, placebo improves performance in older adults, a longevity inflammation gene in long-lived families, and a minimally invasive knee procedure evaluated.

Seven research findings that matter for your longevity strategy this week — oral GLP-1 pills, breast cancer risk reduction, a new Alzheimer's target, vaping's cancer verdict, the Yale aging reversal study, mitochondrial energy restoration, and a 70% preclinical lifespan increase.